X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4450) 4450
Book Review (935) 935
Publication (653) 653
Book Chapter (25) 25
Conference Proceeding (13) 13
Dissertation (9) 9
Magazine Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3588) 3588
animals (2543) 2543
humans (1773) 1773
physiology (1102) 1102
male (1083) 1083
rats (948) 948
mice (752) 752
female (631) 631
glucose (620) 620
biochemistry & molecular biology (570) 570
cotransporter (556) 556
sodium (556) 556
neurosciences (553) 553
pharmacology & pharmacy (543) 543
urology & nephrology (531) 531
expression (526) 526
cell biology (523) 523
diabetes (522) 522
endocrinology & metabolism (507) 507
type 2 diabetes (451) 451
diabetes mellitus, type 2 - drug therapy (428) 428
rodents (372) 372
kidney (368) 368
kidney - metabolism (366) 366
sodium - metabolism (357) 357
proteins (356) 356
analysis (355) 355
rats, sprague-dawley (350) 350
physiological aspects (342) 342
transport (342) 342
double-blind (338) 338
symporters - metabolism (336) 336
cells (333) 333
hypoglycemic agents - therapeutic use (327) 327
dapagliflozin (325) 325
blood-pressure (323) 323
dextrose (320) 320
research (317) 317
sodium-glucose transporter 2 - antagonists & inhibitors (317) 317
article (313) 313
diabetes mellitus (310) 310
hypertension (308) 308
cells, cultured (307) 307
k-cl cotransporter (306) 306
kidneys (290) 290
phosphorylation (276) 276
carrier proteins - metabolism (275) 275
sodium-potassium-chloride symporters - metabolism (274) 274
insulin (273) 273
glucose - metabolism (263) 263
rats, wistar (261) 261
gene expression (260) 260
cell line (245) 245
blood pressure (244) 244
kinetics (243) 243
homeostasis (236) 236
middle aged (235) 235
chlorides - metabolism (233) 233
type 2 diabetes mellitus (226) 226
empagliflozin (224) 224
biological transport (222) 222
xenopus laevis (217) 217
symporters (216) 216
canagliflozin (215) 215
sglt2 inhibitor (213) 213
gaba (212) 212
biophysics (209) 209
type-2 diabetes-mellitus (209) 209
brain (208) 208
mice, inbred c57bl (207) 207
mutation (206) 206
molecular sequence data (205) 205
glycemic control (204) 204
neurons (204) 204
bumetanide - pharmacology (202) 202
hyperglycemia (200) 200
multidisciplinary sciences (200) 200
adult (195) 195
glucosides - therapeutic use (193) 193
transporter (192) 192
health aspects (188) 188
symporters - genetics (188) 188
rat (187) 187
na-k-2cl cotransporter (182) 182
na+/glucose cotransporter (181) 181
hydrogen-ion concentration (180) 180
amino acid sequence (179) 179
disease models, animal (179) 179
metabolism (179) 179
immunohistochemistry (178) 178
hypoglycemic agents - pharmacology (177) 177
bumetanide (176) 176
dose-response relationship, drug (174) 174
rna, messenger - metabolism (174) 174
care and treatment (173) 173
cotransporter 2 inhibitors (173) 173
kinases (173) 173
metformin (172) 172
safety (172) 172
solute carrier family 12, member 2 (172) 172
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4420) 4420
Spanish (15) 15
French (8) 8
German (8) 8
Korean (6) 6
Japanese (5) 5
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Diabetes and Its Complications, ISSN 1056-8727, 2015, Volume 29, Issue 8, pp. 1295 - 1303
Abstract Aims To evaluate the mid long-term efficacy and safety of sodium–glucose cotransporter 2 (SGLT2) inhibitors in adults with type 2 diabetes mellitus... 
Endocrinology & Metabolism | Type 2 diabetes | Efficacy | Safety | Sodium-Glucose cotransporter 2 inhibitors | Meta-analysis | METFORMIN | PLACEBO | ADD-ON | DAPAGLIFLOZIN | SGLT2 INHIBITORS | MELLITUS | INADEQUATE GLYCEMIC CONTROL | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | EMPAGLIFLOZIN | Analysis | Glycosylated hemoglobin | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy
Journal Article
Current Opinion in Nephrology and Hypertension, ISSN 1062-4821, 07/2019, Volume 28, Issue 4, pp. 321 - 327
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
Sodium-glucose cotransporter 2 (SGLT2), which is specifically expressed on the apical side of proximal tubular cells, is involved in the reabsorption of most... 
diabetic kidney disease | sodium-glucose cotransporter 2 (SGLT2) inhibitors | final common pathway | tubuloglomerular feedback (TGF)
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2019, Volume 21, Issue 2, pp. 434 - 438
The extent to which sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors increase the risk of genital infections in routine clinical care, compared with other... 
antidiabetic drug | type 2 diabetes | SGLT2 inhibitor | pharmacoepidemiology | COTRANSPORTER 2 INHIBITORS | EFFICACY | SAFETY | URINARY-TRACT | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | VAGINAL CANDIDIASIS | Glucose transporter | Balanitis | Vulvovaginitis | Peptidase | Sodium | Diabetes mellitus | Infections | Vaginitis | Diabetes mellitus (non-insulin dependent)
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 05/2016, Volume 24, Issue 10, pp. 2242 - 2250
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2017, Volume 19, Issue 8, pp. 1106 - 1115
Aim: To compare the associations of individual sodium-glucose co-transporter-2 (SGLT2) inhibitors with adverse renal outcomes in patients with type 2 diabetes... 
type 2 diabetes | meta‐analysis | renal outcomes | inhibitor | SGLT2 | meta-analysis | SGLT2 inhibitor | LONG-TERM | COTRANSPORTER 2 INHIBITORS | DAPAGLIFLOZIN | SAFETY | MELLITUS | BLOOD-PRESSURE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | POOLED ANALYSIS | CHRONIC KIDNEY-DISEASE | EMPAGLIFLOZIN | Humans | Risk | Renal Insufficiency - prevention & control | Diabetes Mellitus, Type 2 - metabolism | Renal Insufficiency - epidemiology | Benzhydryl Compounds - adverse effects | Renal Insufficiency - chemically induced | Canagliflozin - therapeutic use | Glucosides - therapeutic use | Renal Insufficiency - complications | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Reproducibility of Results | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - chemically induced | Canagliflozin - adverse effects | Evidence-Based Medicine | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Randomized Controlled Trials as Topic | Membrane Transport Modulators - therapeutic use | Diabetic Nephropathies - epidemiology | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Medical colleges | Patient outcomes | Glucose | Risk factors | Dextrose | Diabetes therapy | Clinical trials | Diabetes | Meta-analysis | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1852 - 1858
Aims: To estimate the risk of diabetic ketoacidosis (DKA) associated with sodium-glucose co-transporter-2 (SGLT2) inhibitor treatment compared with the risk... 
cohort study | DPP | antidiabetic drug | SGLT | diabetes complications | 2 inhibitor | 4 inhibitor | SGLT2 inhibitor | DPP-4 inhibitor | SHIFT | DAPAGLIFLOZIN | SGLT2 INHIBITORS | HYPOTHESIS | ENDOCRINOLOGY & METABOLISM | COTRANSPORTER 2 INHIBITION | EMPAGLIFLOZIN | Insurance, Health, Reimbursement | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetic Ketoacidosis - therapy | Incidence | Young Adult | Aged, 80 and over | Adult | Diabetic Ketoacidosis - prevention & control | Female | Retrospective Studies | Diabetic Ketoacidosis - epidemiology | Republic of Korea - epidemiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hospitalization | Diabetes Mellitus, Type 2 - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Diabetic Ketoacidosis - chemically induced | Type 2 diabetes | Diabetic acidosis | Complications and side effects | Medical research | Care and treatment | Ketoacidosis | Diuretics | Medicine, Experimental | Hypoglycemic agents | Glucose | Dextrose | Glucose transporter | Statistical analysis | Peptidase | Diabetes mellitus | Population studies | Patients | Sodium | Microvasculature | Diabetes | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Cardiovascular Research, ISSN 0008-6363, 02/2019, Volume 115, Issue 2, pp. 266 - 276
Abstract There is growing evidence from Phase III randomized clinical trials of the cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2)... 
Systematic review | Sodium glucose cotransporter 2 inhibitors | Preclinical | Cardiovascular diseases | SELECTIVE SGLT2 INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | DAPAGLIFLOZIN | CIRCADIAN-RHYTHM | HEART-FAILURE | ATHEROSCLEROSIS | DIABETIC CARDIOMYOPATHY | BLOOD-PRESSURE | OUTCOMES | NA+/H+ EXCHANGER | EMPAGLIFLOZIN
Journal Article
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, ISSN 1178-7007, 2012, Volume 5, pp. 313 - 327
The kidney plays an important role in glucose metabolism, and has been considered a target for therapeutic intervention. The sodium-glucose cotransporter type... 
Inhibitors | Sodium-glucose cotransporter type 2 | SGLT2 | Oral diabetes agent | Weight loss | Glucosuria | Kidney | Type 2 diabetes | Glucose metabolism | Care and treatment | Carrier proteins | Cellular control mechanisms | Research | Properties | Observations | Glucose | Diabetes | inhibitors | kidney | oral diabetes agent | weight loss | sodium-glucose cotransporter type 2 | glucosuria
Journal Article